Squalene epoxidase as hypocholesterolemic drug target revisited.

[1]  J. Ascaso,et al.  Hypercholesterolemia , 2020, Definitions.

[2]  E. Leitersdorf.  SELECTIVE CHOLESTEROL ABSORPTION INHIBITION: A NOVEL STRATEGY IN LIPID‐LOWERING MANAGEMENT , 2002, International journal of clinical practice.

[3]  James P. Wilson,et al.  FDA Adverse Event Reports on Statin-Associated Rhabdomyolysis , 2002, The Annals of pharmacotherapy.

[4]  J Seki,et al.  Effect of FR194738, a potent inhibitor of squalene epoxidase, on cholesterol metabolism in HepG2 cells. , 2001, European journal of pharmacology.

[5]  D. Wexler,et al.  The Plasma Concentration and LDL‐C Relationship in Patients Receiving Ezetimibe , 2001, Journal of clinical pharmacology.

[6]  T. Sudhop,et al.  Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins) , 2001, European Journal of Clinical Pharmacology.

[7]  N. Gupta,et al.  Garlic and garlic-derived compounds inhibit human squalene monooxygenase. , 2001, The Journal of nutrition.

[8]  T. Ugawa,et al.  YM‐53601, a novel squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in several animal species , 2000, British journal of pharmacology.

[9]  E. Ros,et al.  Intestinal absorption of triglyceride and cholesterol. Dietary and pharmacological inhibition to reduce cardiovascular risk. , 2000, Atherosclerosis.

[10]  I. Abe,et al.  Potent and selective inhibition of squalene epoxidase by synthetic galloyl esters. , 2000, Biochemical and biophysical research communications.

[11]  I. Abe,et al.  Green tea polyphenols: novel and potent inhibitors of squalene epoxidase. , 2000, Biochemical and biophysical research communications.

[12]  T. Porter,et al.  Cloning, heterologous expression, and enzymological characterization of human squalene monooxygenase. , 2000, Archives of biochemistry and biophysics.

[13]  T. T. Nguyen,et al.  The cholesterol-lowering action of plant stanol esters. , 1999, The Journal of nutrition.

[14]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[15]  K. C. Srivastava,et al.  Effect of garlic (Allium sativum) on blood lipids, blood sugar, fibrinogen and fibrinolytic activity in patients with coronary artery disease. , 1998, Prostaglandins, leukotrienes, and essential fatty acids.

[16]  D. Hunninghake,et al.  Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study) , 1998, The American journal of cardiology.

[17]  C. Rao,et al.  Chemopreventive effect of squalene on colon cancer. , 1998, Carcinogenesis.

[18]  A. Sorisky,et al.  Efficacy and safety of a new hydroxymethylglutaryl-coenzyme A reductase inhibitor, atorvastatin, in patients with combined hyperlipidemia: comparison with fenofibrate. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[19]  Y. Fukushima,et al.  Localization of the squalene epoxidase gene (SQLE) to human chromosome region 8q24.1. , 1997, Genomics.

[20]  R. Gregg,et al.  Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro. , 1997, Toxicology and applied pharmacology.

[21]  E. Skrzypczak‐Jankun,et al.  Why drinking green tea could prevent cancer , 1997, Nature.

[22]  R. C. Bush,et al.  RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase. , 1997, The Journal of pharmacology and experimental therapeutics.

[23]  B. Eisele,et al.  Effects of a novel 2,3-oxidosqualene cyclase inhibitor on cholesterol biosynthesis and lipid metabolism in vivo. , 1997, Journal of lipid research.

[24]  B. Holub,et al.  Effect of garlic and fish-oil supplementation on serum lipid and lipoprotein concentrations in hypercholesterolemic men. , 1997, The American journal of clinical nutrition.

[25]  O. Morand,et al.  Ro 48-8.071, a new 2,3-oxidosqualene:lanosterol cyclase inhibitor lowering plasma cholesterol in hamsters, squirrel monkeys, and minipigs: comparison to simvastatin. , 1997, Journal of lipid research.

[26]  P. Morell,et al.  Tissue-specific coordinate regulation of enzymes of cholesterol biosynthesis: sciatic nerve versus liver. , 1996, Journal of lipid research.

[27]  P. Jungnickel.  Cholesterol-Lowering Therapy: Is Therereallya Controversy? , 1996, The Annals of pharmacotherapy.

[28]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[29]  A. Rosenberg,et al.  Intraoperative rhabdomyolysis in a patient receiving pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitor. , 1995, Anesthesia and analgesia.

[30]  T. Takeo,et al.  Absorption of (-)-epigallocatechin gallate into the circulation system of rats. , 1995, Bioscience, biotechnology, and biochemistry.

[31]  J. Désiré,et al.  (Aryloxy)methylsilane derivatives as new cholesterol biosynthesis inhibitors: synthesis and hypocholesterolemic activity of a new class of squalene epoxidase inhibitors. , 1995, Journal of medicinal chemistry.

[32]  R. Gregg,et al.  In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes. , 1995, Toxicology and applied pharmacology.

[33]  G. Levine,et al.  Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. , 1995, The New England journal of medicine.

[34]  J. Sakakibara,et al.  Nucleotide sequence of a cDNA for mouse squalene epoxidase. , 1995, Biochimica et biophysica acta.

[35]  J. Sakakibara,et al.  Molecular Cloning and Expression of Rat Squalene Epoxidase (*) , 1995, The Journal of Biological Chemistry.

[36]  R. Krauss,et al.  Coronary Artery Disease Regression: Convincing Evidence for the Benefit of Aggressive Lipoprotein Management , 1994, Circulation.

[37]  J. Sakakibara,et al.  [Squalene epoxidase: another rate limiting enzyme in cholesterol biosynthesis]. , 1994, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[38]  E. Gordon,et al.  Lipophilic 1,1-bisphosphonates are potent squalene synthase inhibitors and orally active cholesterol lowering agents in vivo. , 1993, The Journal of biological chemistry.

[39]  S. Sivak,et al.  Effect of Garlic on Total Serum Cholesterol , 1993, Annals of Internal Medicine.

[40]  Hayashi Masahiro,et al.  An inhibitor of squalene epoxidase, NB-598, suppresses the secretion of cholesterol and triacylglycerol and simultaneously reduces apolipoprotein B in HepG2 cells. , 1993 .

[41]  G. Littarru,et al.  Evidence of Plasma CoQ10‐Lowering Effect by HMG‐CoA Reductase Inhibitors: A Double‐Blind, Placebo‐Controlled Study , 1993, Journal of clinical pharmacology.

[42]  M. Hayashi,et al.  Effect of an inhibitor of squalene epoxidase, NB-598, on lipid metabolism in Hep G2 cells. , 1992, Chemical & pharmaceutical bulletin.

[43]  T. Langan,et al.  Isoprenoids and astroglial cell cycling: Diminished mevalonate availability and inhibition of dolichol‐linked glycoprotein synthesis arrest cycling through distinct mechanisms , 1991, Journal of cellular physiology.

[44]  Y. Iwasawa,et al.  Effect of a novel squalene epoxidase inhibitor, NB-598, on the regulation of cholesterol metabolism in Hep G2 cells. , 1991, The Journal of biological chemistry.

[45]  Y. Sawasaki,et al.  Hypolipidemic effects of NB-598 in dogs. , 1991, Atherosclerosis.

[46]  N. Bhagavan,et al.  Rhabdomyolysis secondary to lovastatin therapy. , 1990, Clinical chemistry.

[47]  T Kamei,et al.  Regulation of squalene epoxidase in HepG2 cells. , 1990, Journal of lipid research.

[48]  T. Satoh,et al.  Regulation of squalene epoxidase activity in rat liver. , 1990, Journal of lipid research.

[49]  T. Strandberg,et al.  Metabolic variables of cholesterol during squalene feeding in humans: comparison with cholestyramine treatment. , 1990, Journal of lipid research.

[50]  K. K. Larson,et al.  Rhabdomyolysis and acute renal failure induced by combination lovastatin and gemfibrozil therapy. , 1990, Annals of internal medicine.

[51]  S. Grundy.  HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. , 1988, The New England journal of medicine.

[52]  B. Arison,et al.  Isopentenoid synthesis in isolated embryonic Drosophila cells. Farnesol catabolism and omega-oxidation. , 1988, The Journal of biological chemistry.

[53]  W. Stigelman,et al.  Goodman and Gilman's the Pharmacological Basis of Therapeutics , 1986 .

[54]  H. Kosaka,et al.  Purification and partial characterization of squalene epoxidase from rat liver microsomes. , 1982, Biochimica et biophysica acta.

[55]  M. Astruc,et al.  Squalene epoxidase and oxidosqualene lanosterol-cyclase activities in cholesterogenic and non-cholesterogenic tissues. , 1977, Biochimica et biophysica acta.

[56]  K. Bloch,et al.  Solubilization and partial characterization of rat liver squalene epoxidase. , 1975, The Journal of biological chemistry.

[57]  Lampert Pw,et al.  Mechanism of demyelination in tellurium neuropathy. Electron microscopic observations. , 1971 .

[58]  J. Dietschy,et al.  Regulation of cholesterol metabolism. I. , 1970, The New England journal of medicine.

[59]  R. Laaksonen,et al.  Serum ubiquinone concentrations after short- and long-term treatment with HMG-CoA reductase inhibitors , 2004, European Journal of Clinical Pharmacology.

[60]  D. Sica,et al.  Rhabdomyolysis and statin therapy: relevance to the elderly. , 2002, The American journal of geriatric cardiology.

[61]  D. Botstein,et al.  The transcriptional program in the response of human fibroblasts to serum. , 1999, Science.

[62]  B. Eisele,et al.  Effects of a novel 2,3-oxidosqualene cyclase inhibitor on the regulation of cholesterol biosynthesis in HepG2 cells. , 1996, Journal of lipid research.

[63]  A. Neil,et al.  Garlic as a Lipid Lowering Agent—A Meta-Analysis , 1994, Journal of the Royal College of Physicians of London.

[64]  M. Battino,et al.  Exogenous CoQ10 preserves plasma ubiquinone levels in patients treated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors , 1994, International journal of clinical & laboratory research.

[65]  Y. Iwasawa,et al.  Mammalian squalene epoxidase inhibitors and structure-activity relationships , 1993 .

[66]  W. Moore,et al.  Terminal difluoro olefin analogs of squalene are time-dependent inhibitors of squalene epoxidase , 1992 .

[67]  W. Schafer,et al.  Protein prenylation: genes, enzymes, targets, and functions. , 1992, Annual review of genetics.

[68]  T. Ono,et al.  Squalene epoxidase from rat liver microsomes. , 1985, Methods in enzymology.

[69]  J. Crouse,et al.  Measurement of squalene in human tissues and plasma: validation and application. , 1976, Journal of lipid research.